To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we
compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly …

Dipeptidyl peptidase-4 (DPP-4) inhibitors may affect the serum levels of plasminogen
activator inhibitor-1 (PAI-1) associated with triglyceride (TG) metabolism, which is a …

Vildagliptin is an orally active, potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor,
shown to be effective and well tolerated in patients with type 2 diabetes mellitus (T2DM) as …

Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the
treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted …

Results After a 12-week treatment, vildagliptin-treated rats showed a significant reduction in
blood glucose and blood lipid levels. Moreover, vildagliptin recovered aortic endothelial …

Objective Vildagliptin is a potent and selective dipeptidyl peptidase-IV (DPP-4) inhibitor that
improves glycemic control in patients with type 2 diabetes mellitus by increasing α-and β-cell …

Type 2 diabetes is characterized by chronic hyperglycemia due to the body s progressive
inability to efficiently utilize insulin. The majority of individuals who develop this form of …

Objective: To highlight the role of incretin hormones in the management of type 2 diabetes
mellitus with a focus on vildagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor currently in …

Vildagliptin is a potent, orally active inhibitor of dipeptidyl peptidase-4 (DPP-4) for the
treatment of type 2 diabetes mellitus. It has been reported that vildagliptin can cause hepatic …

Abstract Aims/Hypothesis: Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that
augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic …